Royalty Pharma plc
RPRX
NASDAQ
Healthcare
$57.77
+3.57%gain today
Market position
Market cap rank
#537
of 2,614
1-day
+3.57%
1-month
+6.96%
6-month
+49.51%
YTD
+48.66%
1-year
+59.63%
5-year
+38.94%
Key figures
Market cap
$24.85B
P/E (live)
24.8
price ÷ annual EPS
P/E (reported)
16.6
FY 2025
EPS
$2.33
FY 2025
Dividend yield
2.27%
FY 2025
Dividend / share
$0.91
Gross margin
100.00%
FY 2025
Operating margin
65.58%
FY 2025
Net margin
32.42%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$25.02B
FY 2025
EV / EBITDA
15.30
FY 2025
EV / Sales
10.52
FY 2025
Price / book
2.58
FY 2025
Price / sales
7.02
FY 2025
Earnings yield
4.62%
FY 2025
FCF yield
14.92%
FY 2025
Debt / equity
1.38
FY 2025
Current ratio
0.97
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$2.38B
Gross profit
$2.38B
Operating income
$1.56B
EBITDA
$1.64B
Net income
$770.95M
Diluted EPS
$1.80
Shares outstanding
431,887,000
Trading
Open
$56.12
Previous close
$55.78
Day range
$55.62 – $57.80
52-week range
$34.08 – $57.80
50-day avg
$53.24
200-day avg
$44.22
Volume
3,192,909
Avg volume
3,731,886
Beta
0.42
Price history
+59.63% over 1Y
Compare with peers
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Visit websiteCompany info
CEO
Pablo Legorreta
IPO date
Jun 16, 2020
Headquarters
New York, NY, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
